Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IzotropicFRA:1R3 30 EV-to-EBIT is -8.38 as of Aug. 25, 2026. GuruFocus rates FRA:1R3 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 106 Medical Diagnostics & Research companies, Izotropic ranks worse than 943395.28% on this metric.
The historical rank and industry rank for Izotropic's EV-to-EBIT or its related term are showing as below:
FRA:1R3'
s EV-to-EBIT Range Over the Past 10 Years
Min: -8.75 Med: 0 Max: 0
Current: -8.44
FRA:1R3's EV-to-EBIT is ranked worse than 100% of 106
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.975
vs FRA:1R3: -8.44
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Izotropic's Enterprise Value for the quarter that ended in Jan. 2026 was €10.76 Mil.
Izotropic's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Izotropic EV-to-EBIT Related Terms
Izotropic EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Izotropic's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Izotropic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Izotropic EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Izotropic's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Izotropic's EV-to-EBIT falls into.
Izotropic's current Enterprise Value is €11.90 Mil.
Izotropic's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Izotropic (FRA:1R3) has a EV-to-EBIT of -8.38 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Izotropic and its competitors. According to the industry distribution chart, Izotropic ranks #999999 out of 106 companies in the Medical Diagnostics & Research industry.
Is Izotropic's EV-to-EBIT too high?
Izotropic's current EV-to-EBIT is -8.38. Based on the distribution chart, Izotropic ranks #999999 out of 106 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Izotropic has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Izotropic's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Izotropic ranks #999999 out of 106 companies for EV-to-EBIT. This places Izotropic in the lower half of its industry. The industry median EV-to-EBIT is 22.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.98, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Izotropic and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Izotropic's current EV-to-EBIT is -8.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Izotropic stock overvalued right now?
Izotropic (FRA:1R3) has a current EV-to-EBIT of -8.38. The current EV-to-EBIT is -8.38. Izotropic's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Izotropic (FRA:1R3), the current EV-to-EBIT is -8.38 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Izotropic Corp is a research and development company specializing in cancer research and early detection for breast cancer. It is engaged in advancing breast cancer imaging through the commercialization of medical imaging technologies. The company's current focus is on the commercialization of its first medical imaging device, IzoView, a dedicated Breast CT Imaging System, developed to provide high resolution, true 3D volumetric visualization of the breast without compression for breast cancer detection and diagnosis.
30GF Score
Get the complete analysis for FRA:1R3
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1R3 has been successfully added to your 
